The Methodist Hospital System. Leading Medicine

Even the smallest stroke can damage brain tissue and impair cognitive function

Posted on January 16, 2013 in stroke-app

Even the smallest stroke can damage brain tissue and impair cognitive function

Blocking a single tiny blood vessel in the brain can harm neural tissue and even alter behavior, a new study from the University of California, San Diego has shown. But these consequences can be mitigated by a drug already in use, suggesting treatment that could slow the progress of dementia associated with cumulative damage to miniscule blood vessels that feed brain cells. The team reports their results in the December 16 advance online edition of Nature Neuroscience.

“The brain is incredibly dense with vasculature. It was surprising that blocking one small vessel could have a discernable impact on the behavior of a rat,” said Andy Y. Shih, lead author of the paper who completed this work as a postdoctoral fellow in physics at UC San Diego. Shih is now an assistant professor at the Medical University of South Carolina.

Working with rats, Shih and colleagues used laser light to clot blood at precise points within small blood vessels that dive from the surface of the brain to penetrate neural tissue. When they looked at the brains up to a week later, they saw tiny holes reminiscent of the widespread damage often seen when the brains of patients with dementia are examined as a part of an autopsy.

These micro-lesions are too small to be detected with conventional MRI scans, which have a resolution of about a millimeter. Nearly two dozen of these small vessels enter the brain from a square millimeter area of the surface of the brain.

“It’s controversial whether that sort of damage has consequences, although the tide of evidence has been growing as human diagnostics improve,” said David Kleinfeld, professor of physics and neurobiology, who leads the research group.

To see whether such minute damage could change behavior, the scientists trained thirsty rats to leap from one platform to another in the dark to get water.

The rats readily jump if they can reach the second platform with a paw or their snout, or stretch farther to touch it with their whiskers. Many rats can be trained to rely on a single whisker if the others are clipped, but if they can’t feel the far platform, they won’t budge.

“The whiskers line up in rows and each one is linked to a specific spot in the brain,” Shih said. “By training them to use just one whisker, we were able to distill a behavior down to a very small part of the brain.”

When Shih blocked single microvessels feeding a column of brain cells that respond to signals from the remaining whisker, the rats still crossed to the far platform when the gap was small. But when it widened beyond the reach of their snouts, they quit.

The FDA-approved drug memantine, prescribed to slow one aspect of memory decline associated with Alzheimer’s disease, ameliorated these effects. Rats that received the drug jumped whisker-wide gaps, and their brains showed fewer signs of damage.

“This data shows us, for the first time, that even a tiny stroke can lead to disability,” said Patrick D. Lyden, a co-author of the study and chair of the department of neurology at Cedars-Sinai Medical Center in Los Angeles. “I am afraid that tiny strokes in our patients contribute—over the long term—to illness such as dementia and Alzheimer’s disease,” he said, adding that “better tools will be required to tell whether human patients suffer memory effects from the smallest strokes.”

“We used powerful tools from biological physics, many developed in Kleinfeld’s laboratory at UC San Diego, to link stroke to dementia on the unprecedented small scale of single vessels and cells,” Shih said. “At my new position at MUSC, I plan to work on ways to improve the detection of micro-lesions in human patients with MRI. This way clinicians may be able to diagnose and treat dementia earlier.” –Susan Brown

 

###

Additional authors include Pablo Blinder, Beth Friedman, Geoffrey Stanley and Philbert S. Tsai, all at UC San Diego. The National Institutes of Biomedical Imaging and Bioengineering, Mental Health, and Neurological Disease and Stroke provided primary funding through grants to Kleinfeld (EB003832, MH085499, and OD006831). Shih was further supported by a postdoctoral fellowship from the American Heart Association.

Share and Enjoy

  • Facebook
  • Twitter
  • StumbleUpon
  • Email
  • Reddit
  • Pinterest

Investigational Human Adult Stem Cell Therapy Studied in Ischemic Stroke Patients

Posted on January 16, 2013 in stroke-app
Investigational Human Adult Stem Cell Therapy Studied in Ischemic Stroke Patients
Released: 3/6/2012 10:25 AM EST
Source: Methodist Hospital, Houston

Newswise — Physicians at the Methodist Neurological Institute are studying the use of human stem cells as a possible treatment for acute ischemic stroke, a leading cause of death and disability. Each year, stroke affects more than 15 million people around the world.
Patients whose ischemic strokes occur within one to two days of being admitted to The Methodist Hospital in Houston may be eligible to enroll in the double-blind, randomized, placebo-controlled phase 2 safety and efficacy trial of MultiStem®, a novel therapy being developed by Athersys, Inc.

“The thrombolytic tPA is still the only FDA-approved treatment for the majority of stroke cases, but unfortunately, we only have a three hour window of opportunity with this drug,” said Dr. David Chiu, medical director of the Eddy Scurlock Stroke Center at Methodist and the study site’s principal investigator. “By offering our acute stroke patients a broader timeframe for treatment, we hope to have the chance to effectively help many more patients.”

The study will examine the effects of intravenous administration of adult stem cells that can be manufactured from a donor. In contrast to traditional bone marrow transplants, which require one donor for each patient that needs treatment, MultiStem is a patented formulation of early adult stem cells, and hundreds of thousands to millions of doses can be made from the bone marrow cells of one healthy donor. The product can be made in advance, and may be stored in the hospital and used “off the shelf”.

Researchers in the clinical trial will not only look at how well the investigational therapy works for stroke treatment, but they will also monitor for potential side effects and how potent the drug is compared to placebo.

Another goal of this study is to examine some of the stem cells’ effects on organs such as the spleen, which is thought to contribute to ongoing inflammation that could increase brain injury after the initial stroke. Published work from preclinical studies shows that MultiStem can provide benefits even when administered several days after a stroke has occurred, and some of the cell effects appear to occur through their action on the spleen. Animal models used in this research showed a statistically significant and durable improvement in motor skills relative to animals that received a placebo.

More than 80 percent of stroke patients have ischemic strokes, where a clot causes an obstruction in an artery leading to the brain, restricting blood flow. On average, someone suffers a stroke every 40 seconds in the United States, and someone dies of a stroke every three to four minutes. Each year, about 795,000 people experience a new or recurrent stroke.

Stroke is the fourth leading cause of death and the leading cause of serious long-term disability in the United States, costing the nation an estimated $74 billion each year.

About the Methodist Neurological Institute Eddy Scurlock Stroke Center
With 18 beds, the Eddy Scurlock Stroke Center at the Methodist Neurological Institute in Houston is the largest dedicated stroke unit in the Texas Medical Center and designated a certified primary stroke center by Det Norsk Veritas. The Center is a leader in all areas of stroke research, including diagnosis, innovative treatment, prevention, rehabilitation and recovery. The Methodist NI and its stroke outreach education programs at all Methodist system hospitals are also the beneficiaries of the Taking Strides4Stroke Community Awareness Campaign, which promotes education and awareness of stroke symptoms, treatment, prevention and research.

For more information, visit the Eddy Scurlock Stroke Center or call 713-790-3333. Follow us on Twitter and Facebook.

Share and Enjoy

  • Facebook
  • Twitter
  • StumbleUpon
  • Email
  • Reddit
  • Pinterest